Usefulness of PET With [18F]LBT-999 for the Evaluation of Presynaptic Dopaminergic Neuronal Loss in a Clinical Environment
Purpose: The density of the neuronal dopamine transporter (DAT) is directly correlated with the presynaptic dopaminergic system injury. In a first study, we evaluated the brain distribution and kinetics of [18F]LBT-999, a DAT PET radioligand, in a group of eight healthy subjects. Taking into account...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-08-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2020.00754/full |
| _version_ | 1818849960285700096 |
|---|---|
| author | Maria-Joao Ribeiro Maria-Joao Ribeiro Maria-Joao Ribeiro Johnny Vercouillie Johnny Vercouillie Johnny Vercouillie Nicolas Arlicot Nicolas Arlicot Nicolas Arlicot Clovis Tauber Valérie Gissot Valérie Gissot Karl Mondon Laurent Barantin Laurent Barantin Jean-Philippe Cottier Jean-Philippe Cottier Serge Maia Jean-Bernard Deloye Patrick Emond Patrick Emond Denis Guilloteau Denis Guilloteau Denis Guilloteau |
| author_facet | Maria-Joao Ribeiro Maria-Joao Ribeiro Maria-Joao Ribeiro Johnny Vercouillie Johnny Vercouillie Johnny Vercouillie Nicolas Arlicot Nicolas Arlicot Nicolas Arlicot Clovis Tauber Valérie Gissot Valérie Gissot Karl Mondon Laurent Barantin Laurent Barantin Jean-Philippe Cottier Jean-Philippe Cottier Serge Maia Jean-Bernard Deloye Patrick Emond Patrick Emond Denis Guilloteau Denis Guilloteau Denis Guilloteau |
| author_sort | Maria-Joao Ribeiro |
| collection | DOAJ |
| description | Purpose: The density of the neuronal dopamine transporter (DAT) is directly correlated with the presynaptic dopaminergic system injury. In a first study, we evaluated the brain distribution and kinetics of [18F]LBT-999, a DAT PET radioligand, in a group of eight healthy subjects. Taking into account the results obtained in healthy volunteers, we wanted to evaluate whether the loss of presynaptic striatal dopaminergic fibers could be estimated, under routine clinical conditions, using [18F]LBT-999 and a short PET acquisition.Materials and methods: Six patients with Parkinson's disease (PD) were compared with eight controls. Eighty-nine minutes of dynamic PET following an intravenous injection of [18F]LBT-999 were acquired. Using regions of interest for striatal nuclei, substantia nigra (SN), cerebellum, and occipital cortex, defined over each T1 3D MRI, time–activity curves (TACs) were obtained. From TACs, binding potential (BPND) using the simplified reference tissue model and distribution volume ratios (DVRs) using Logan graphical analysis were calculated. Ratios obtained for a 10-min image, acquired between 30 and 40 min post-injection, were also calculated. Cerebellum activity was used as non-specific reference region.Results: In PD patients and as expected, striatal uptake was lower than in controls which is confirmed by BPND, DVR, and ratios calculated for both striatal nuclei and SN, significantly inferior in PD patients compared with controls (p < 0.001).Conclusions: PET with [18F]LBT-999 could be an alternative to assess dopaminergic presynaptic injury in a clinical environment using a single 10 min acquisition. |
| first_indexed | 2024-12-19T06:41:32Z |
| format | Article |
| id | doaj.art-3b7e621efc8e41288c0d9972cc466b78 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-19T06:41:32Z |
| publishDate | 2020-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-3b7e621efc8e41288c0d9972cc466b782022-12-21T20:32:04ZengFrontiers Media S.A.Frontiers in Neurology1664-22952020-08-011110.3389/fneur.2020.00754528772Usefulness of PET With [18F]LBT-999 for the Evaluation of Presynaptic Dopaminergic Neuronal Loss in a Clinical EnvironmentMaria-Joao Ribeiro0Maria-Joao Ribeiro1Maria-Joao Ribeiro2Johnny Vercouillie3Johnny Vercouillie4Johnny Vercouillie5Nicolas Arlicot6Nicolas Arlicot7Nicolas Arlicot8Clovis Tauber9Valérie Gissot10Valérie Gissot11Karl Mondon12Laurent Barantin13Laurent Barantin14Jean-Philippe Cottier15Jean-Philippe Cottier16Serge Maia17Jean-Bernard Deloye18Patrick Emond19Patrick Emond20Denis Guilloteau21Denis Guilloteau22Denis Guilloteau23UMR 1253, iBrain, Université de Tours, Tours, FranceCHRU, Tours, FranceInserm CIC 1415, CHRU, Tours, FranceUMR 1253, iBrain, Université de Tours, Tours, FranceCHRU, Tours, FranceInserm CIC 1415, CHRU, Tours, FranceUMR 1253, iBrain, Université de Tours, Tours, FranceCHRU, Tours, FranceInserm CIC 1415, CHRU, Tours, FranceUMR 1253, iBrain, Université de Tours, Tours, FranceCHRU, Tours, FranceInserm CIC 1415, CHRU, Tours, FranceCHRU, Tours, FranceUMR 1253, iBrain, Université de Tours, Tours, FranceCHRU, Tours, FranceUMR 1253, iBrain, Université de Tours, Tours, FranceCHRU, Tours, FranceCHRU, Tours, FranceZionexa, Saint-Beauzire, FranceUMR 1253, iBrain, Université de Tours, Tours, FranceCHRU, Tours, FranceUMR 1253, iBrain, Université de Tours, Tours, FranceCHRU, Tours, FranceInserm CIC 1415, CHRU, Tours, FrancePurpose: The density of the neuronal dopamine transporter (DAT) is directly correlated with the presynaptic dopaminergic system injury. In a first study, we evaluated the brain distribution and kinetics of [18F]LBT-999, a DAT PET radioligand, in a group of eight healthy subjects. Taking into account the results obtained in healthy volunteers, we wanted to evaluate whether the loss of presynaptic striatal dopaminergic fibers could be estimated, under routine clinical conditions, using [18F]LBT-999 and a short PET acquisition.Materials and methods: Six patients with Parkinson's disease (PD) were compared with eight controls. Eighty-nine minutes of dynamic PET following an intravenous injection of [18F]LBT-999 were acquired. Using regions of interest for striatal nuclei, substantia nigra (SN), cerebellum, and occipital cortex, defined over each T1 3D MRI, time–activity curves (TACs) were obtained. From TACs, binding potential (BPND) using the simplified reference tissue model and distribution volume ratios (DVRs) using Logan graphical analysis were calculated. Ratios obtained for a 10-min image, acquired between 30 and 40 min post-injection, were also calculated. Cerebellum activity was used as non-specific reference region.Results: In PD patients and as expected, striatal uptake was lower than in controls which is confirmed by BPND, DVR, and ratios calculated for both striatal nuclei and SN, significantly inferior in PD patients compared with controls (p < 0.001).Conclusions: PET with [18F]LBT-999 could be an alternative to assess dopaminergic presynaptic injury in a clinical environment using a single 10 min acquisition.https://www.frontiersin.org/article/10.3389/fneur.2020.00754/fullParkinson's diseasedopamineDATPETradiopharmaceutical |
| spellingShingle | Maria-Joao Ribeiro Maria-Joao Ribeiro Maria-Joao Ribeiro Johnny Vercouillie Johnny Vercouillie Johnny Vercouillie Nicolas Arlicot Nicolas Arlicot Nicolas Arlicot Clovis Tauber Valérie Gissot Valérie Gissot Karl Mondon Laurent Barantin Laurent Barantin Jean-Philippe Cottier Jean-Philippe Cottier Serge Maia Jean-Bernard Deloye Patrick Emond Patrick Emond Denis Guilloteau Denis Guilloteau Denis Guilloteau Usefulness of PET With [18F]LBT-999 for the Evaluation of Presynaptic Dopaminergic Neuronal Loss in a Clinical Environment Frontiers in Neurology Parkinson's disease dopamine DAT PET radiopharmaceutical |
| title | Usefulness of PET With [18F]LBT-999 for the Evaluation of Presynaptic Dopaminergic Neuronal Loss in a Clinical Environment |
| title_full | Usefulness of PET With [18F]LBT-999 for the Evaluation of Presynaptic Dopaminergic Neuronal Loss in a Clinical Environment |
| title_fullStr | Usefulness of PET With [18F]LBT-999 for the Evaluation of Presynaptic Dopaminergic Neuronal Loss in a Clinical Environment |
| title_full_unstemmed | Usefulness of PET With [18F]LBT-999 for the Evaluation of Presynaptic Dopaminergic Neuronal Loss in a Clinical Environment |
| title_short | Usefulness of PET With [18F]LBT-999 for the Evaluation of Presynaptic Dopaminergic Neuronal Loss in a Clinical Environment |
| title_sort | usefulness of pet with 18f lbt 999 for the evaluation of presynaptic dopaminergic neuronal loss in a clinical environment |
| topic | Parkinson's disease dopamine DAT PET radiopharmaceutical |
| url | https://www.frontiersin.org/article/10.3389/fneur.2020.00754/full |
| work_keys_str_mv | AT mariajoaoribeiro usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT mariajoaoribeiro usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT mariajoaoribeiro usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT johnnyvercouillie usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT johnnyvercouillie usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT johnnyvercouillie usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT nicolasarlicot usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT nicolasarlicot usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT nicolasarlicot usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT clovistauber usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT valeriegissot usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT valeriegissot usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT karlmondon usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT laurentbarantin usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT laurentbarantin usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT jeanphilippecottier usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT jeanphilippecottier usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT sergemaia usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT jeanbernarddeloye usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT patrickemond usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT patrickemond usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT denisguilloteau usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT denisguilloteau usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment AT denisguilloteau usefulnessofpetwith18flbt999fortheevaluationofpresynapticdopaminergicneuronallossinaclinicalenvironment |